Sofinnova Partners
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
Latent Labs raises £40m Series A led by Radical Ventures and Sofinnova Partners to advance AI protein design
Latent Labs develops AI foundation models for generative protein design, enabling biotech and pharmaceutical teams to computationally design new antibodies, enzymes and therapeutics more efficiently.
More venture news
- 14 May 2026
IceotopeIceotope raises £19m Series B led by Two Seas Capital and Barclays Climate Ventures for liquid cooling systems for AI data infrastructure
Series BAI - 11 May 2026
Isomorphic LabsIsomorphic Labs raises £1.5bn Series B led by Thrive Capital for AI models that design new drug candidates
Series BLife Sciences - 1 Apr 2026
Sona secures a £34m Series B led by N47 for workforce management software focussed on frontline businesses
Series BEnterprise
